Clinical Takeaway
People with PTSD and co-occurring substance use disorders who use cannabis can still benefit meaningfully from trauma-focused treatments, and cannabis use does not appear to undermine treatment outcomes compared to non-users. Clinicians should not withhold or delay evidence-based trauma-focused care for patients simply because they are using cannabis.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis directly addresses a critical clinical gap by examining whether evidence-based trauma-focused treatments retain efficacy in patients with comorbid PTSD, cannabis use, and other substance use disorders, populations frequently excluded from or underrepresented in randomized trials. The findings have immediate implications for treatment selection and patient counseling, as they clarify whether clinicians should modify standard PTSD protocols or maintain fidelity to evidence-based approaches when cannabis use co-occurs with other SUDs. Understanding treatment efficacy across cannabis use status is essential for optimizing outcomes in the substantial proportion of trauma-exposed patients presenting with polysubstance use.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 While this meta-analysis addresses an important clinical gap by examining trauma-focused treatment outcomes in patients with concurrent PTSD, cannabis use, and other substance use disorders, several limitations warrant careful interpretation. The analysis draws from only four RCTs within a larger meta-analytic framework, which constrains statistical power and generalizability compared to the full Project Harmony dataset, and the abstract does not specify whether cannabis use was active, recent, or historical at baseline, a distinction that substantially affects treatment engagement and outcomes. Cannabis use patterns are highly heterogeneous in terms of frequency, potency, and route of administration, yet these variables are rarely standardized across trials, making it difficult to establish dose-response relationships or identify which patients might be most vulnerable to poor treatment response. From a practical standpoint, clinicians should continue offering evidence-based trauma-focused treatments to patients with PTSD and concurrent cannabis use while maintaining heightened vigilance for non-response, actively assessing whether active cannabis use is interfering with therapeutic engagement, and considering staged treatment
| |